MEDVidi Review
GLP-1 weight-loss telehealth · Independently scored 4.4/10
MEDVidi falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the plan
Medication
Charged on top
Clinician visits
In the price
Shipping
Charged on top
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Each visit carries its own charge instead of a bundled subscription: 195 dollars to start, 159 dollars for a follow-up. Because the prescription travels to whichever pharmacy the patient picks, the drug is billed apart. Providers holding licenses evaluate patients and write phentermine, Qsymia and Saxenda alongside the brand-name Wegovy (semaglutide) and Zepbound (tirzepatide). The footprint is 33 states. Do not confuse the brand with MEDVi (medvi.com), which is a different one.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to MEDVidi
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
MEDVidi at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Zepbound, Wegovy
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Consult
- FDA status
- No FDA warning letter on record
How MEDVidi scores
Six columns, each one computed from something MEDVidi has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10No monthly price is published at all, so value cannot be measured against the register. Capped rather than scored.
Effectiveness25%
5.0/10Publishes no medication list or price, so what is prescribed here cannot be established. Held at the midpoint — this is a gap in the record, not a finding about the drugs.
User Experience15%
5.0/10Where this seller first shows a price is not recorded yet, so the signup is unscored and sits at the midpoint.
Trust & Safety15%
4.0/10does not name a dispensing pharmacy; withholds price until after the intake. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
5.0/10No published price, so what a price would include cannot be assessed. Held at the midpoint.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on MEDVidi
Last checked July 2026- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
GLP-1 medications MEDVidi offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
In its favor
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers consult
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- Billed separately from the monthly figure: medication, shipping
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
What MEDVidi charges
MEDVidi does not publish a standing monthly price. That is a choice, and it means you cannot compare it against anything until you have gone through an intake and been quoted. When you get that quote, ask specifically for the ongoing monthly figure and what it includes — not the first-month rate, and not a program total divided by its length.
What MEDVidi dispenses
MEDVidi prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market.
What we could verify
MEDVidi publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to compare prices before committing time to an intake — there is no published figure to compare.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want the price to stop moving as your dose climbs
Our read
We cannot tell you whether MEDVidi is priced well, because it does not say. That is not automatically disqualifying — plenty of legitimate operators quote after intake — but it does mean the comparison has to happen after you have spent the time, which is the wrong order for the buyer. CoreAge Rx is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
MEDVidi falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay MEDVidi
Check today's price, then book the free consultation.
Where MEDVidi is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this MEDVidi review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
See MEDVidi's current pricing
The free consultation is where you learn whether you qualify, and what it costs today.